Arcadia Biosciences (NASDAQ:RKDA) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note published on Monday morning. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Arcadia Biosciences in a research note on Wednesday, August 21st.

Arcadia Biosciences Stock Performance

Arcadia Biosciences stock opened at $3.18 on Monday. The stock has a market capitalization of $4.33 million, a P/E ratio of -0.62 and a beta of 1.34. The company’s fifty day moving average price is $2.84 and its 200 day moving average price is $2.72. Arcadia Biosciences has a 1 year low of $1.85 and a 1 year high of $3.93.

Arcadia Biosciences (NASDAQ:RKDA) last announced its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.27 by ($0.49). The company had revenue of $1.31 million during the quarter, compared to analyst estimates of $0.95 million. Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. During the same quarter last year, the business earned ($2.64) EPS. Sell-side analysts predict that Arcadia Biosciences will post -1.7 EPS for the current year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.